abstract |
The present invention belongs to the technical field of medicine, and specifically relates to a quinazoline-based EGFR tyrosine kinase inhibitor containing a zinc binding group represented by general formula (I), its deuterated product, its pharmaceutically acceptable salt or its stereoisomer body, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , W, X, L and T are as defined in the specification; the present invention also relates to the preparation method of these compounds, containing these compounds pharmaceutical preparations, and the use of these compounds in the preparation of medicines for treating and/or preventing tumors. |